Feasibility and effectiveness of a digital voice assistant for improving anti-osteoporosis medication adherence, and osteoporosis knowledge and attitudes, in postmenopausal women with osteoporosis: A 12-month randomised controlled trial

IF 3.1 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Archives of Osteoporosis Pub Date : 2025-04-09 DOI:10.1007/s11657-025-01529-0

Melkamu Tamir Hunegnaw, Jakub Mesinovic, Paul Jansons, Elena S. George, Belinda De Ross, Nicole Kiss, Peter R. Ebeling, Robin M. Daly, Eugene Gvozdenko, David Scott

{"title":"Feasibility and effectiveness of a digital voice assistant for improving anti-osteoporosis medication adherence, and osteoporosis knowledge and attitudes, in postmenopausal women with osteoporosis: A 12-month randomised controlled trial","authors":"Melkamu Tamir Hunegnaw, Jakub Mesinovic, Paul Jansons, Elena S. George, Belinda De Ross, Nicole Kiss, Peter R. Ebeling, Robin M. Daly, Eugene Gvozdenko, David Scott","doi":"10.1007/s11657-025-01529-0","DOIUrl":null,"url":null,"abstract":"<div><h3>Summary</h3><p>Digital voice assistants (DVAs) are feasible for delivering a digital health intervention designed to improve osteoporosis self-management in postmenopausal women with osteoporosis. However, the DVA intervention did not improve anti-osteoporosis drug adherence, nor did it enhance osteoporosis knowledge or attitudes in this population.</p><h3>Purpose</h3><p>To determine feasibility and effectiveness of a digital voice assistant (DVA) intervention for improving anti-osteoporosis medication adherence, and osteoporosis knowledge and attitudes, in postmenopausal women with osteoporosis.</p><h3>Methods</h3><p>This 12-month single-blinded, randomised controlled trial included 50 postmenopausal women with osteoporosis randomised to DVA (N = 25) or control (N = 25) for 6 months, followed by a 6-month follow-up period. DVA participants received an Amazon Alexa device that delivered osteoporosis education videos, medication reminders and interactive quizzes. Control participants received emails with links to osteoporosis information. Anti-osteoporosis medication possession ratio (MPR; acceptable adherence defined as ≥ 0.8) was determined using Pharmaceutical Benefits Schedule data. Osteoporosis knowledge was measured using the Osteoporosis Knowledge Assessment Tool (OKAT) and medication attitudes were measured using the Adherence Evaluation of Osteoporosis Treatment (ADEOS-12) questionnaire.</p><h3>Results</h3><p>The mean ± SD age of participants was 64.3 ± 6.1 years and 6-month DVA intervention adherence (number of DVA sessions accessed) was 79.5% (95%CI: 73.9, 84.9). The proportion of participants with acceptable 12-month MPRs was similar between groups (control: 86.4% [95%CI: 77.0, 93.6]; DVA: 95.0% [95%CI: 88.4, 100.0], <i>P</i> = 0.34). Mean OKAT scores improved in both groups after both 6- and 12 months, but there were no significance between groups. Changes in mean ADEOS-12 scores did not differ between baseline and 6 months in DVA compared to control (0.61 [95%CI: − 0.80, 2.03]) but worsened post-intervention from 6 to 12 months (net difference: − 1.42 [95%CI: − 2.80, − 0.06]).</p><h3>Conclusions</h3><p>This DVA-delivered intervention achieved good adherence but did not improve medication adherence, osteoporosis knowledge, or attitudes compared with control. Future studies should target populations with poor adherence to anti-osteoporosis medication.\n</p></div>","PeriodicalId":8283,"journal":{"name":"Archives of Osteoporosis","volume":"20 1","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s11657-025-01529-0.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Osteoporosis","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s11657-025-01529-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Summary

Digital voice assistants (DVAs) are feasible for delivering a digital health intervention designed to improve osteoporosis self-management in postmenopausal women with osteoporosis. However, the DVA intervention did not improve anti-osteoporosis drug adherence, nor did it enhance osteoporosis knowledge or attitudes in this population.

Purpose

To determine feasibility and effectiveness of a digital voice assistant (DVA) intervention for improving anti-osteoporosis medication adherence, and osteoporosis knowledge and attitudes, in postmenopausal women with osteoporosis.

Methods

This 12-month single-blinded, randomised controlled trial included 50 postmenopausal women with osteoporosis randomised to DVA (N = 25) or control (N = 25) for 6 months, followed by a 6-month follow-up period. DVA participants received an Amazon Alexa device that delivered osteoporosis education videos, medication reminders and interactive quizzes. Control participants received emails with links to osteoporosis information. Anti-osteoporosis medication possession ratio (MPR; acceptable adherence defined as ≥ 0.8) was determined using Pharmaceutical Benefits Schedule data. Osteoporosis knowledge was measured using the Osteoporosis Knowledge Assessment Tool (OKAT) and medication attitudes were measured using the Adherence Evaluation of Osteoporosis Treatment (ADEOS-12) questionnaire.

Results

The mean ± SD age of participants was 64.3 ± 6.1 years and 6-month DVA intervention adherence (number of DVA sessions accessed) was 79.5% (95%CI: 73.9, 84.9). The proportion of participants with acceptable 12-month MPRs was similar between groups (control: 86.4% [95%CI: 77.0, 93.6]; DVA: 95.0% [95%CI: 88.4, 100.0], P = 0.34). Mean OKAT scores improved in both groups after both 6- and 12 months, but there were no significance between groups. Changes in mean ADEOS-12 scores did not differ between baseline and 6 months in DVA compared to control (0.61 [95%CI: − 0.80, 2.03]) but worsened post-intervention from 6 to 12 months (net difference: − 1.42 [95%CI: − 2.80, − 0.06]).

Conclusions

This DVA-delivered intervention achieved good adherence but did not improve medication adherence, osteoporosis knowledge, or attitudes compared with control. Future studies should target populations with poor adherence to anti-osteoporosis medication.

查看原文本刊更多论文

数字语音助手改善绝经后骨质疏松妇女抗骨质疏松药物依从性、骨质疏松知识和态度的可行性和有效性：一项为期12个月的随机对照试验

数字语音助手（DVAs）可用于提供旨在改善绝经后骨质疏松症妇女骨质疏松症自我管理的数字健康干预。然而，DVA干预并没有提高抗骨质疏松药物依从性，也没有提高该人群对骨质疏松的认识或态度。目的探讨数字语音助手（DVA）干预对改善绝经后骨质疏松妇女抗骨质疏松药物依从性、骨质疏松知识和态度的可行性和有效性。方法：这项为期12个月的单盲、随机对照试验纳入50名绝经后骨质疏松症妇女，随机分为DVA组（N = 25）和对照组（N = 25），为期6个月，随访6个月。DVA的参与者收到了一台亚马逊Alexa设备，该设备可以发送骨质疏松症教育视频、药物提醒和互动测验。对照组的参与者收到了含有骨质疏松症信息链接的电子邮件。抗骨质疏松药物持有率；可接受依从性定义为≥0.8)使用药物获益表数据确定。采用骨质疏松知识评估工具（Osteoporosis knowledge Assessment Tool， OKAT）测量骨质疏松知识，采用骨质疏松治疗依从性评估（ADEOS-12）问卷测量用药态度。结果参与者的平均±SD年龄为64.3±6.1岁，6个月DVA干预依从性（获得DVA疗程数）为79.5% （95%CI: 73.9, 84.9）。可接受的12个月MPRs的参与者比例在两组之间相似(对照组：86.4% [95%CI: 77.0, 93.6]；Dva: 95.0% [95%ci: 88.4, 100.0], p = 0.34)。在6个月和12个月后，两组的OKAT平均得分均有所提高，但两组之间没有显著性差异。与对照组相比，基线和6个月DVA的平均ADEOS-12评分变化无差异（0.61 [95%CI: - 0.80, 2.03]），但干预后6至12个月恶化（净差：- 1.42 [95%CI: - 2.80, - 0.06]）。结论与对照组相比，dva干预获得了良好的依从性，但没有改善药物依从性、骨质疏松知识或态度。未来的研究应该针对抗骨质疏松药物依从性差的人群。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Archives of Osteoporosis ENDOCRINOLOGY & METABOLISMORTHOPEDICS -ORTHOPEDICS

CiteScore

5.50

自引率

10.00%

发文量

133

期刊介绍： Archives of Osteoporosis is an international multidisciplinary journal which is a joint initiative of the International Osteoporosis Foundation and the National Osteoporosis Foundation of the USA. The journal will highlight the specificities of different regions around the world concerning epidemiology, reference values for bone density and bone metabolism, as well as clinical aspects of osteoporosis and other bone diseases.